Suppression of Human Glioma Xenografts with 2nd Generation IL13R-Specific Chimeric Antigen Receptor-Modified T Cells

Seogkyoung Kong¹, Sadhak Sengupta¹, Betty Tyler⁸, Anthony J Bais², Qiangzhong Ma², Saryn Doucette³, Jinyuan Zhou², Ayguen Sahin⁶, Bob S. Carter⁶, Henry Brem⁴, Richard P. Junghans⁷*, Prakash Sampath¹

¹ Brain Tumor Lab, Department of Neurosurgery, ² Biotherapeutics Development Lab, Department of Medicine, and ³ Department of Pathology, Boston University School of Medicine, Roger Williams Medical Center, Providence, RI; ⁴ Hunterian Neurosurgical Research Laboratory, Department of Neurosurgery, and ⁵ Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD; ⁶ Department of Neurosurgery, Massachusetts General Hospital, Boston, MA

Running Title: Glioma suppression by IL13Rα2-targeted designer T cells.

*Corresponding Author:
Dr R P Junghans, Department of Medicine, Boston University School of Medicine, Roger Williams Medical Center, 825 Chalkstone Avenue, NC 143, Providence, RI 02908, Fax: 401-456-4812. E-mail: rpi@bu.edu

Keywords: chimeric antigen receptor, zetakine, IL13 receptor targeting, designer T cells, glioblastoma, human glioma xenograft model

The authors have no conflicts of interest to declare.
TRANSLATIONAL RELEVANCE

Targeted immunotherapy has received a great deal of interest in recent years with the aim to apply a cytotoxic agent that preferentially targets tumor cells, without damage to the surrounding brain tissue. Chimeric antigen receptors (CAR) that are fusion products of an antibody or ligand binding domain with the zeta signaling chain of the T cell receptor (TCR) is a promising strategy for targeted immunotherapy of malignant tumors. Resulting “designer T cells” (dTc) are redirected by the neo-specificity to attack tumors expressing the surface antigen recognized by the CARs. This strategy is designed to bypass a major drawback of cancer immunotherapy, which has been hampered by the fact that most “tumor antigens” are normal self-proteins to which the patient is already tolerized. IL13 receptor alpha-2 (IL13Rα2) was selected as a target antigen because it is highly overexpressed in 60-85% of gliomas. This same receptor is minimally or not expressed in normal brain tissue making it a suitable candidate for targeting with immunotherapy. Successful application of such dTc in animal models can be encouraging for their translation into human clinical settings for treatment of resection cavity or recurrent gliomas.
ABSTRACT

Purpose: Glioblastoma multiforme (GBM) remains highly incurable, with frequent recurrences after standard therapies of maximal surgical resection, radiation, and chemotherapy. To address the need for new treatments, we have undertaken a chimeric antigen receptor (CAR) “designer T cell” (dTc) immunotherapeutic strategy by exploiting IL13Ra2 as a GBM-selective target.

Experimental Design: We tested a 2nd generation IL13 “zetakine” CAR comprised of a mutated IL13 extracellular domain linked to intracellular signaling elements of the CD28 co-stimulatory molecule and CD3ζ. The aim of the mutation (IL13.E13K.R109K) was to enhance selectivity of the CAR for recognition and killing of IL13Ra2+ GBM, while sparing normal cells bearing the composite IL13Ra1/IL4Ra receptor.

Results: Our aim was partially realized with improved recognition of tumor and reduced but persisting activity against normal tissue IL13Ra1+ cells by the IL13.E13K.R109K CAR. We demonstrate that these IL13 dTc were efficient in killing IL13Ra2+ glioma cell targets with abundant secretion of cytokines IL2 and IFNy, and they displayed enhanced tumor-induced expansion versus control unmodified T cells in vitro. In an in vivo test with a human glioma xenograft model, a single intracranial injection of IL13 dTc into tumor sites resulted in marked increases in animal survivals.

Conclusions: These data raise the possibility of immune targeting of diffusely invasive GBM cells either (a) via dTc infusion into resection cavities to prevent GBM recurrence or (b) via direct stereotactic injection of dTc to suppress inoperable or recurrent tumors. Systemic administration of these IL13 dTc could be complicated by reaction against normal tissues expressing IL13Ra1.

Abbreviations: CAR, chimeric antigen receptor; dTc, designer T cell; E:T, effector-to-target; GBM, glioblastoma multiforme (glioma); gen, generation; MHC, major histocompatibility complex; TIL, tumor-infiltrating lymphocyte; UnTd, untransduced.
INTRODUCTION

Glioblastoma multiforme (GBM) is the most common and lethal of adult brain cancers. GBM is currently treated with surgical resection, radiation, and chemotherapy (1). Despite recent advances with multimodality interventions, the majority of patients survive less than 20 months due to tumor recurrence (2, 3). Therefore, new therapies are needed to prevent such recurrence and improve patient survivals. Here, we report a strategy of genetic modification of T cells (“designer T cells”) to redirect their killing specificity against GBM cells while leaving the normal cells of the brain unharmed.

T cells can be modified using viral or plasmid vectors to express a chimeric antigen receptor (CAR), providing a large population of patient-derived designer T cells (dTc) with the power to recognize tumor-specific antigens (4). The CAR is a single molecule comprising an extracellular tumor-antigen binding domain, a transmembrane domain, and cytoplasmic signaling domains for T cell activation. The resulting modified T cells are redirected by the neo-specificity of the CAR to attack tumors expressing the surface antigen. T cell recognition is mediated in a major histocompatibility complex (MHC)-independent fashion, resulting in a more broadly applicable therapy that also avoids mechanisms of tumor escape via down-regulation of MHC-I that has been reported in glioblastomas (5). Direct, loco-regional delivery of GBM-specific T cells into the surgical bed at the time of tumor resection has the potential to eradicate residual, invasive glioblastoma cells and prevent tumor recurrence. Glioma specific dTc therapy is being actively pursued in both preclinical studies and clinical trials (6-8).

Interleukin (IL) 13 receptor α2 (IL13Rα2) is a GBM-associated protein that is overexpressed on virtually all GBM tumors but minimally or not at all in normal brain tissues (9,10). As such, IL13Rα2 was considered suitable as a GBM-selective antigen, a rationale that has supported
the targeting of GBM within the CNS in the clinical development of IL13 immunotoxin molecules (11) and IL13 designer T cells (6).

The GBM associated receptor has a moderate to high affinity for IL13 ($K_d = 0.25 - 1.2 \text{ nM}$) (12). The widespread, normal tissue-associated receptor, IL13Rα1, is structurally distinct, with an approximate 10-fold lower affinity for IL13 ($K_d = 2-30 \text{ nM}$) (13-15). In the presence of IL4 receptor, however, IL13Rα1 will form a ternary complex with IL13 ($\text{IL13Rα1/IL13/IL4Rα}$) that is of very high affinity ($K_d = 0.1 - 0.4 \text{ nM}$) (13, 14). In context with IL4Rα, IL13Rα1 will bind IL4 as well as IL13, but as an isolated receptor, IL13Rα1 will bind only IL13. IL13Rα2 is always an isolated receptor and only binds IL13.

In this study, we adapt a previously described “zetakine” approach (6) to express an IL13 CAR on dTcs to provide recognition and targeting of IL13Rα2 on GBM tumors. Previous studies have shown that substitutions at different sites in IL13 could either enhance IL13 binding to IL13Rα2 or block IL13 binding to IL4Rα that generates the high affinity IL13Rα1/IL4Rα receptor (15-17). Using this information, we created a novel mutant (IL13.E13K.R109K) to improve the selectively for IL13Rα2 on GBM versus IL13Rα1/IL4Rα on normal tissues. Further, we incorporated a CD28 signaling domain into the CAR to provide Signal 2 co-stimulation with CD3ζ Signal 1 for improved dTc survival and function. Finally, we created monomeric and dimeric forms of the CAR to test hypotheses of CAR receptor binding and activation. In vitro testing and an in vivo model for intracranial loco-regional administration provide data that are encouraging for ultimate human application.
METHODS

Cell Lines and Cultures.

The human glioma cell line U251 was obtained from H Brem (Johns Hopkins). Thp-1, HUVEC, 293 and Daudi cell lines were obtained from American Type Culture Collection (Rockville, MD).

Construction of Chimeric Antigen Receptor Gene in Expression Vector. cDNA clone encoding full-length hIL13 was obtained from Open Biosystems (Huntsville, AL) (GenBank ID: NM 002188). The mutant IL13.E13K.R109K was created by PCR with mutagenic primers based on the hIL13 cDNA sequence. The transmembrane and cytoplasmic domains were amplified by PCR from hCD3ζ cDNA clone obtained from ATCC (GenBank ID: BC025703). The human cytoplasmic CD28 chain, the hinge region of human CD8α, and an Ig heavy chain signal sequence (VHCAMP) were amplified by PCR from pMFG-CEA (18). Each product was digested with restriction enzymes, ligated, and amplified by PCR. Monomeric CAR was generated by mutating both Cys-29 of the CD8α hinge and Cys-2 of CD3 transmembrane to Ala using mutagenic primers. The assembled construct was sequenced then cut and ligated into BamHI-NotI cleaved MFG retroviral expression vector.

Retrovirus Production and Genetic Modification of Primary Human T cells

Retroviral supernatants were prepared and peripheral blood T cells activated and transduced as previously (19). Human peripheral blood mononuclear cells (PBMCs) were Ficoll-isolated from blood-filter discards (Rhode Island Blood Center, Providence, RI) then activated in the presence of OKT3 (10 μg/ml) and IL2 (300 U/ml) for 36-48 h. Cultured cells were then “spinfected” by centrifugation with retrovirus-containing supernatants plus protamine in a retronectin-coated plate for 1h at room temperature. This step was repeated two further times in the next 24 h, and then transferred to fresh RPMI-1640 medium containing 10% fetal bovine serum, antibiotics and
IL2 (300 IU/ml) with a 10-20-fold expansion over 1-2 weeks period. After one week in culture, cultures were >95% T cells, as used in the assays. Activated untransduced (UnTd) T cells from the same isolation were used as control group in all experiments.

**Western Blot**

Transduced T cells ($10^7$) were coincubated overnight with tunicamycin, an inhibitor of N-linked glycosylation, then processed to membrane fractions of protein using Mem-per Protein Extraction (Thermo-Fisher) per manufacturer’s instructions, then analyzed as previously (18).

**Flow Cytometric Analysis**

Flow cytometry employed an LSR II instrument (Becton Dickinson) and FACSDiva software (Becton Dickinson). PE-conjugated antihuman IL13 antibody (Becton Dickinson) was used to detect CAR expression on transduced T cells. U251 and Thp-1 cell lines were analyzed with anti-human IL13Rα2 antibody (R&D Systems) with anti-mouse FITC secondary antibody (R&D Systems), or anti-human IL13Rα1 phycoerythrin (R&D Systems). In all cases, negative controls included isotype antibodies.

**Cytotoxicity Assay for Redirected Tumor Cell Killing**

The cytolytic activity of T cell effectors was determined by CytoTox-GloTM Cytotoxicity Assay (Promega, Madison, WI). Effector cells were plated in 96-well plates at 37°C for 22 hours in triplicate at 5,000/well with 10,000 U251 or HUVEC target cells (E:T 0.5:1); or for 5 hours in triplicate at 50,000/well with 10,000 target cells (E:T 5:1).

**Analysis of Cytokine Production**

Untransduced (UnTd) activated T cells and CAR+ T cell effectors ($2 \times 10^5$) were co-cultured in
96-well plates with target cells (1 x 10^5) in duplicate in 200 μl of culture medium (E:T 2:1). After 24 hr, supernatants were assayed for IL2 and IFNγ by ELISA (R&D Systems). The media in Figure 3 were supplemented with IL2 that was subtracted as a background reading on control cultures without cell targets (ca. 200 pg/ml). Adjustment was then made for CAR+ fractions (20-24%) as necessary for construct comparisons. See Supplemental online material for detailed explanation of controls and data reduction to create this Figure. In Figure 4, cytokine assays did not include IL2, yielding IL2 levels in unstimulated dTc and control UnTd T cells <10 pg/ml. In this figure, results with dTc were not adjusted for CAR+ fraction (~30%).

**Proliferation and Expansion Assays**

Activated T cell effectors (1 x 10^6) were cocultured IL2 with irradiated (7,000 rads) target cells (5 x 10^5) in 24-well plates in 1 ml of culture medium, supplemented with 5 IU/mL (E:T 2:1). The T cell cultures were restimulated on day 7 with fresh irradiated targets. Viable T cells were assayed by trypan blue exclusion. The starting and final CAR+ fractions were assessed by flow cytometry.

**Calculations of CAR+ Cell Expansions**

With a mixture of normal and CAR+ T cells, an antigen-induced difference in the expansion rate of the modified cells is revealed in the net change in total cell numbers. The fold-change of the dTc component from baseline (day 0) is given by y_2 = 1/f_1 (y_3 – y_1 (1-f_1)), in which y_1 is the fold-increase of cells in the control culture, y_3 is the fold-increase of total cells in the stimulated culture, and f_1 is the original fraction of CAR+ cells in the mix. Using values of 13, 20 and 0.03, respectively, from Fig. 4C&D, a value of y_2 = 250-fold increase in dTc is derived. Compared to the control expansion, there is n = y_2/y_1 = 250/13 = 19-fold greater expansion of the dTc over this time period due to stimulation. When considered in terms of growth rate constants (e.g., k in
the impact is seen as \( k_2/k_1 = \log(y_2)/\log(y_1) \) in this formulation, with a \( \log(250)/\log(13) = 2.1 \)-fold increase in the growth rate constant with antigen stimulation, comparable to values previously derived with CEA- and GD3-specific dTc (18, 27). (For derivations, see Appendix. See also Emtage et al [18].)

We also consider the reverse method of inferring the impact of stimulation to increase dTc proliferation from the higher fraction of CAR+ cells. The relative fold-increase in dTc \( (y_2/y_1) \) is given as \( n = [(1-f_1)/f_1] \cdot [f_2/(1-f_2)] \), in which \( f_1 \) and \( f_2 \) are the starting and ending CAR+ fractions. When applied to data of Fig. 4D (subtracting backgrounds), \( f_1 = 0.03 \) and \( f_2 = 0.38 \), yielding an \( n = 20 \)-fold relative expansion in dTc versus control over the assay period post stimulation, corroborating the above result \( n=19 \). (This contrasts with a smaller, 12.7-fold change in percentage [3% to 38%]. The CAR+ fraction changes more slowly than the fold-increase in CAR+ cells because the new CAR+ cells increase the denominator as well as the numerator.) (For derivations see Appendix. See also Emtage et al [18].)

**Intracranial Glioma Model**

Female nude rats, 125 - 175 grams (Charles River Laboratories, Wilmington, MA) were anesthetized and the head shaved and prepared with alcohol and Prepodyne solution (West Penetone, Montreal, Canada). A midline scalp incision was made, exposing the sagittal and coronal sutures. A 2 mm burr hole was made with an electric drill, centered 3 mm lateral to the sagittal suture, and 5 mm posterior to the coronal suture, avoiding the sagittal sinus. Rats were then placed in a stereotactic frame (David Kopf, Tujunga, CA), and \( 1 \times 10^8 \) U251 glioblastoma cells suspended in 5 ul culture medium were injected over 3 minutes via a 26-gauge needle inserted to a depth of 3 mm at the center of the burr hole. Following the injection, the needle was left in place for 3 min to avoid tumor cell extrusion, then withdrawn and the incision closed with
surgical staples. Experiments were performed under protocols approved by the Animal Care and Use Committee of Johns Hopkins University.

**In Vivo Efficacy Study**

Six days after tumor injection, the tumor bearing-rats were randomized into 3 groups for treatment with $5 \times 10^6$ T cells (32% modification; n=13); or $5 \times 10^6$ UnTd activated T cells in 25 µL (n=12) at the same tumor coordinates; or no treatment (n=6). Rats were observed for systemic and neurologic toxicity, and death was recorded. At Day 120, the experiment was terminated and surviving rats were euthanized.

**Magnetic Resonance Imaging**

Two rats per group were selected at random for MR imaging at 1, 2, and 3 weeks following treatment, under isofluothane anesthesia. Multi-slice T2-weighted imaging with fast spin echo acquisition was acquired.

**Brain Histology and Immunohistochemistry**

Two rats per group selected at random were anesthetized with pentobarbital (100 mg/kg i.p.) and perfused transcardially with 4% paraformaldehyde. Brain tissue was harvested, fixed in 10% formalin, blocked in paraffin, sectioned in a coronal plane in 5-µm sections, and stained with H&E and anti-CD3. Brain histology experiments were performed by Johns Hopkins Medical Laboratories Reference Histology, and immunostaining performed in the Roger Williams Medical Center Pathology Department.

**Statistical Analysis**

Cytotoxicity and cytokine production results were expressed as mean ± standard error of the
mean (SEM) and analyzed using Student's t-test. A p-value less than 0.05 was considered statistically significant. For in vivo efficacy, death was the primary end point. The distribution of the intervals until death was analyzed by the method of Kaplan and Meier.
RESULTS

A central concern for any redirected cellular therapy is the specificity of the targets for tumorous versus normal expression of antigen on essential organs. The potency and accompanying potential for hazard of the dTc platform was graphically demonstrated with the death of the first patient treated with dTc expressing a CAR against Her2/neu, which has low expression in the lung, bowel and heart tissues that were targeted (20). Accordingly, a major focus is rightly on the selectivity of the CAR for IL13Ra2, with distribution largely restricted to GBM, versus the normal IL13Ra1/IL4Ra that is expressed widely in the body.

Previous studies showed that substitutions at two sites (Lys-105 and Arg-109) in IL13 could enhance IL13 binding to IL13Ra2; while substitution at Glu-13 in IL13 could decrease IL13 binding to the IL4Ra component of the high affinity IL13Ra1/IL4Ra receptor (15-17, 21, 22). Therefore, we designed a novel mutant IL13.E13K.R109K (Glu-13 and Arg-109 both changed to Lys) that we hypothesized would enhance selectivity for recognition of IL13Ra2 of GBM.

Additionally, we assessed a further change to improve the potency of the dTc. The IL13Ra2 that is expressed on glioblastomas is monomeric in structure. We speculated that monomeric CARs interacting with this monomeric receptor might allow for a tighter clustering of CAR signaling domains for improved dTc signaling and activation. Alternatively, CARs already in dimeric form might better present cytoplasmic domains for cluster-initiated signaling, increasing domain concentrations locally.

To address these hypotheses, we planned monomeric (m) and dimeric (d) IL13 wildtype (Wt = IL13.CD28.ζ) and mutant (Mu = IL13.E13K.R109K.CD28.ζ) CARs comprising an extracellular wt or mutant IL13 molecule linked to intracellular signaling components from CD28 co-stimulatory
molecule and the CD3ζ molecule. We incorporated CD28 signaling into the CAR since tumor cells do not typically express B7, the natural ligand for CD28. This 2nd generation (gen) CAR transmits TCR signal 1 and CD28 signal 2 to resist activation-induced T cell death (AICD), providing prolonged anti-tumor effect (18, 23-26).

**Creation of IL13.CD28,ζ designer T cells**

To create the dimeric wildtype (dWt) IL13.CD28,ζ CAR, we adapted our prior MFG retroviral CD28,ζ vector that supplies intracellular signaling components from the CD28 cytoplasmic domain and the CD3ζ domain in a colinear design (18) (Fig.1A). In place of the CD28 TM and ECD of our prior constructs (18, 27), we substituted a CD3ζ TM domain to maintain CAR dimerization without an ECD; with CD28 TM, the ECD is needed for dimerization to occur. This condensed format allowed us to study the impact of the presence or absence of an extracellular spacer on IL13 CAR expression and function.

Initial optimization studies compared the native IL13 leader with the canonical Immunoglobulin heavy chain leader employed in our other constructs (18, 27), and compared the CAR expression with the presence or absence of a CD8a hinge domain. OKT3-activated T cells from a healthy donor were transduced with the MFG vectors to generate functional IL13.CD28,ζ CAR+ dTc. Expression was determined by staining with anti-IL13 antibody (Fig.1B). These tests proved critical for optimal gene expression. The heavy chain leader was much superior to the native IL13 leader for surface expression. Further, there was little surface staining without the hinge domain, suggesting poor surface transit for this CAR or steric hindrance in antibody binding from the IL13-to-membrane juxtaposition. This format with heavy chain leader plus hinge spacer was employed for all ensuing studies.
Next we examined the possibility to create a monomeric CAR (Fig. 2A). For this, we mutated the cysteines to alanine (Cys → Ala) in the CD3ζ TM and in the extracellular CD8α hinge region that maintain dimerization of the CAR. As the final variation, we created a mutant IL13 (IL13.E13K.R109K) that includes alterations to improve the reactivity against IL13Ra2+ gliomas (R109K), while reducing attack against normal tissues bearing IL13Ra1/IL4Ra (E13K) (22). When the CARs were expressed, Western blotting on non-reducing gels confirmed monomeric (~40 kDa) and dimeric (~80 kDa) products (Fig. 2B). Allowing for differences in vector supernatant titers, all formats were equally well-expressed by fluorescence intensity of surface staining on flow cytometry (Fig. 2C).

**Signaling is equivalent between monomeric and dimeric CARs, but superior with mutant IL13 CARs.**

To select an agent for development, we tested the aforementioned hypotheses of action in a T cell stimulation assay with IL2 secretion as read-out. Functional tests were performed with bulk modified T cells with a mixed population of CD4 and CD8 cells, reflecting current practice of clinical trials to infuse bulk modified T cells (28) that shift to inverted CD8/CD4 ratios on extended culture (27). Four configurations were tested for signaling potential by IL2 secretion: monomer wildtype (mWt) IL13 CAR, dimer wildtype (dWt) IL13 CAR, monomer mutant (mMu) IL13 CAR, and dimer mutant (dMu) IL13 CAR. Normal human T cells were modified to 20-25%, and mixed 1:1 with stimulator target cells. Fig. 3A shows IL13 receptor profiles for stimulator cells used in this study: Thp-1 (IL13Ra1+a2-) and U251 (IL13Ra1-a2+). These represent the normal tissue and tumor-predominant IL13 receptors, respectively.

IL2 secretion was abundant with all four of the constructs on both IL13R positive cell lines (Fig. 3B) (see Materials and Methods). Within each wt or mutant pair, the monomeric and
dimeric CARs were equivalent, with no difference in signaling potential by this read-out, thus falsifying our hypothesis of a particular advantage to either the monomeric or dimeric format. In contrast, the mutant IL13 displayed characteristics that supported our hypothesis of an improved selectivity of the mutant form, with heightened signaling on the IL13Rα2+ cell targets and reduced signaling on the IL13Rα1+ cells. Both of the IL13 wt CARs (monomer and dimer) had signaling activity against IL13R α1+ and α2+ targets, as expected, with the Thp-1 α1+ targets more potently activating the IL13 CAR+ T cells. In both of the mutant IL13 CARs, the signaling pattern was reversed, with the dTc each more potently activated by the U251 IL13R α2+ target than by the α1+ target. Thus, the mutant IL13 CARs were half as efficiently activated on IL13Rα1+ Thp-1 cells and twice as efficiently activated on IL13Rα2+ U251 cells, a four-fold improvement in selectivity.

The preferred form for development was thus mutant IL13 CAR in either monomeric or dimeric format. For the remainder of the exposition, we present data on one form (monomer mutant, mMu IL13 CAR) that was taken forward from in vitro through in vivo testing.

**Functional characterization of monomer mutant (mMu) IL13.CD28.ζ designer T cells**

Insertion of mMu IL13.CD28.ζ CAR into T cells genetically programs the resulting dTc to respond in an MHC-independent manner to IL13Rα2+ glioblastoma cells with activation of T cell effector functions. We assayed three mechanisms relevant to antitumor activity of IL13 dTc: cytotoxicity, cytokine production and proliferation/resistance to AICD.

The single most critical feature of CAR+ T cells for antitumor therapy is their antigen-directed killing capacity. We demonstrate that IL13 CAR+ T cells recognize and kill IL13Rα2+ glioblastoma cells (Fig. 4A). U251 cells were 60% killed in 5 hr with an effector-to-target (E:T)
ratio of 5:1 that calculates to 1.25:1 dTc to targets, when allowing for fact that cells were 24% modified (Fig. 4A left). In a longer term assay with a lower E:T ratio of 0.5:1 (0.2:1 when adjusted for dTc fraction), 75% of targets were killed in 22 hr, showing multiple tumor cell (~3.5) killing per T cell in this interval (Fig.4A right). Activated UnTd T cells showed negligible killing under both conditions.

Cytokine production was assessed in terms of IL2 and interferon gamma (IFNγ) released by activated dTc. IL2 is an essential growth factor for T cell survival and proliferation, and secretion of IL2 and IFNγ has been correlated with tumor rejection (29-31). Previous studies showed that IL2 is produced principally by CD4 helper T cells and that IFNγ may be secreted by both CD4 and CD8 cells upon antigen engagement (31). Bulk unfractionated IL13 dTc were cultured with target cells and supernatants assayed by ELISA. The IL13 dTc produced IL2 (confirming results of Fig.3) and IFNγ when cultured with IL13Ra2+ U251 cells but not when cultured with IL13Ra- HUVEC cells (Fig.4B). UnTd control T cells were negative for cytokine production on both targets.

A primary motivation for the 2nd gen format with CD28 co-stimulation was to avoid activation-induced cell death (AICD) and to foster dTc expansion on antigen contact. To test the potential for such expansion, we designed an experiment with co-culture of T cells and IL13Ra2+ targets, beginning with an intentionally low 3% dTc starting fraction and then monitoring total cell numbers and dTc fractions over time. Creation of dTc involves a general activation of all T cells followed by vector transduction (Methods) that continues with a basal expansion of all T cells, modified and unmodified, over a month’s period. In co-cultures, IL13 dTc proliferated 13-fold on Daudi cells over two weeks due to this basal expansion that increased to 20-fold on U251 cells (Fig. 4C). When adjusting for the 3% CAR+ fraction, this
increment in the dTc culture implied a 250-fold increase in the original CAR+ T cells versus 13-fold in the unmodified cells. This corresponds to an n = 19-fold relative numeric increase (250/13) over the period and a doubling of the basal dTc expansion rate constant induced by tumor contact (i.e., 8.0 vs 3.7 doublings; see Methods for calculations).

Proof of the selectively accelerated dTc growth is reflected in an enrichment of the dTc fraction by flow cytometry (Fig. 4D). Over two weeks, the 3% starting fraction of CAR+ T cells (after background subtraction) increased to 38% (after background) on U251 targets, but remained stable (4% after background) on antigen-negative Daudi cells. This enrichment calculates to an n = 20-fold relative expansion of CAR+ T cells on stimulation versus control, corroborating the above result (n=19) (see Methods for calculations).

A single intracranial injection of mMu IL13 designer T cells increases survival in a human glioma xenograft model

To determine the in vivo antiglioma efficacy of locally injected mMu IL13 dTc, we used a human glioma xenograft model as described (32). 1 x 10^6 IL13Rα2+ U251 glioblastoma cells were stereotactically injected in the midbrain of 6 to 8 week old nude rats. On day 6 after tumor implantation (study day 0), rats were randomized into 3 groups for treatment with 5 x 10^6 IL13 dTc (32% modified, 80-90% viability, n=13); 5 x 10^6 UnTd activated T cells (>95% viability, n=12); and no treatment (n=6). T cells were injected to the tumor bed via the same stereotactic coordinates.

Two rats from each group were sacrificed at one week following T cell injections for evaluation of tumor size and T cell infiltration. H&E staining confirmed that IL13 dTc inhibited tumor growth: signs of tumor cell killing were found in rats treated with dTc but not in control animals treated...
with UnTd activated T cells (Fig. 5A). Adjacent sections were stained with anti-CD3 antibody to
determine the persistence and trafficking of T cells within the glioma; tumors were infiltrated both
with UnTd activated T cells and with dTc, but with the modified T cells in much greater
abundance, suggesting improved dTc persistence or tumor-induced expansion (Fig. 5A).

Tumor volume change was followed over time by magnetic resonance imaging (MRI) (Fig. 5B).
By MRI, no tumor was visualized in rats treated with dTc until 3 weeks following treatment. In
contrast, tumors were apparent after one week and grew progressively to large size in animals
that were either untreated or treated with UnTd activated T cells (Fig. 5B).

Finally, this delayed growth of tumor on MRI was reflected in prolonged survival of the dTc
treated animals. Rats that were untreated or treated with UnTd activated T cells had median
survivals of 35 days (range, 35-38; n=4) and 40 days (range, 29-53; n=10), respectively (Fig. 5C,
Table 1). The five day improved survival in the T cell treatment group was statistically
significant (p = 0.025; Table 1), compatible with a non-specific LAK-type activity of activated T
cells against tumor. In contrast, rats treated with IL3 dTc had a median survival of 88 days
(range, 47-120+; n=11), with 28% surviving >120 days (p < 0.0001 vs. UnTd activated T cells;
Table 1), indicating that the IL13 CAR confers important antitumor activity on the injected T cells.
DISCUSSION

In this report, we describe the development and testing of designer T cells expressing a novel IL13Rα2-directed CAR, designated mMu IL13.CD28.ζ, as a promising therapeutic modality for GBM treatment. Following optimization tests, we obtained good expression of the CAR in normal human T cells, utilizing an immunoglobulin heavy chain leader sequence, and interposing a flexible hinge between the IL13 cytokine and the membrane. The immunoglobulin heavy chain leader was superior to the native IL13 leader, and there was little surface staining without the hinge domain. It was not distinguished whether the hinge improved surface transit or overcame a steric factor caused by membrane proximity that otherwise hampered access of antibody to its IL13 binding epitope.

The introduction of mutations in the IL13 domain improved the selectivity of the CAR for IL13Rα2 on tumor versus the IL13Rα1/IL4Rα that is expressed systemically. The R109K mutation has been shown to improve the affinity of IL13 for the IL13Rα2 receptor and the E13K mutation was shown to decrease affinity for the widespread IL13Rα1/IL4Rα (17, 21). By putting these mutations together, we hoped to increase the potency of the IL13 dTc against GBM targets while decreasing the activity against the normal tissue IL13Rα1/IL4Rα. With IL2 response as a signaling readout, that increase was two-fold against IL13Rα2+ cells and the decrease was two-fold against IL13Rα1+ cells, for a four-fold swing in activity. This led to selection of the mutant for further development. Similar comparisons of activity in monomeric or dimeric formats showed no differences, and a monomeric mutated form was applied in further studies.

This IL13 dTc showed levels of cytokine production, tumor cell killing and tumor-dependent T cell expansion compatible with results seen in our other 2nd gen dTc (18, 27). A single...
intracranial tumor injection of these IL13 zetakine/dTc into tumor-bearing rats resulted in a marked increase in survival in a human glioma xenograft model, including 28% long term survivors that potentially represent cures. These survival benefits paralleled a heightened persistence and/or expansion of dTc in the tumor bed that in turn correlated with the in vitro studies showing that tumor induces selective expansion or persistence of the modified cells.

The quantitative benefit of the mutations in terms of signaling merits discussion. Similarly, the R109K mutation is said to increase IL13 affinity for IL13Rα2 by nearly 30-fold (9), yet we observe only a two-fold benefit in dTc activation on U251 GBM cells. If we take as nominal the IL13 $K_d$ for IL13Rα2 as 1 nM, for IL13Rα1 as 10 nM and for IL13Rα1/IL4Rα as 0.1 nM, and then eliminate the binding to IL4Rα with the E13 mutation, we are still left with binding of IL13 by IL13Rα1 with a 10 nM $K_d$. As presented, this is a 100-fold swing in affinity away from the IL13Rα1/IL4Rα receptor, yet the IL13 dTc on IL13Rα1+ Thp-1 cells show only a two-fold reduction in activation by our measure. The discrepancies are likely to lie in the multivalent nature of the CAR interaction with the antigen on the tumor cell that may obscure differences that are apparent with monovalent ligands (e.g., IL13 immunotoxin). It was previously shown that CAR or TCR affinity above a certain threshold (~10 nM $K_d$) does not increase T cell activation by cellular antigens (33), and that below this threshold that activation is achieved with a product of receptors times affinity, in a mass-action type of formulation (34). Further, it may be noted that even 10 nM $K_d$ ($10^6$ M$^{-1}$ $K_a$) still greatly exceeds typical TCR affinities ($10^5$ to $10^7$ M$^{-1}$ $K_a$). We should therefore not be surprised that the residual binding activity for the normal IL13Rα1 receptor in our mutant IL13 retains substantial.

These data merit comparison with the results of Jensen and colleagues (6), who coined the term zetakine and were the first to prepare an IL13 CAR. In their studies, they employed a 1st gen
version of the IL13 dTc versus our 2nd gen version. They employed a single E13Y mutant versus our double mutant that employed E13K with R109K. The E13Y was selected to reduce affinity for the normal tissue IL13Ra1/IL4Ra, like the E13K that we employ, whereas we add the second mutation in an attempt to increase CAR affinity for the GBM receptor that could improve reactivity against tumor with lesser amounts of antigen. They, like we, also had a hinge spacer, but one (Fc) which generates solely a dimeric format (which we show is equivalent to monomeric). Finally, they applied plasmid transfer for limited duration expression instead of retroviral transfer, as in our case, that provides stable CAR expression.

In terms of cytotoxicity and IFNg production, our data parallel that of Kahlon et al (6). We show abundant IL2 production as expected for 2nd gen that would not be expected with their earlier 1st gen design, yet they show good production as well. Interestingly, they explained their result by the presence of ligands on the cell lines that interact with costimulatory molecule NKG2D on the T cells to provide signal 2. They show 3H-thymidine incorporation in their dTc on antigen contact, but this is not quantitated in terms of actual cell number increases, and repair synthesis associated with apoptosis has been noted to incorporate thymidine (35); in any case, the proliferative response, if any, could have benefited from costimulation in the same fashion as did IL2 secretion. In the end, Kahlon et al showed excellent responses in animal models analogous to ours, with intracranial injection of established tumors, including complete tumor suppressions. Potential advantages in our product are the double mutant, in which the higher affinity of our second mutation is shown to improve signaling, which may be important for attacking low antigen expressing tumors; the incorporation of costimulation, which may be critical for activity in tumors lacking costimulatory ligands; and the retroviral delivery, which yields dTc with permanent modification, thus able to maintain anti-tumor surveillance for prolonged periods.
The results reported here are encouraging for human application against recurrent or resected malignant gliomas, with the demonstration of sufficient power to eliminate residual tumor by intratumoral injections. Yet, some discussion is warranted regarding the selectivity of our CAR for the intended tumor target in such clinical applications. At some level, the improvement in selectivity we have shown may be deemed an advantage. However, the recognition by dTc with the mutated CAR against normal tissue IL13Rα1 remains substantial, and no presumption of safety for normal tissues can be inferred. The consequences of an error in that assumption have the potential to be fatal, depending upon how the dTc are applied (20, 36), and we would accordingly not propose to apply this construct systemically. An alternative, however, may be to recapitulate our model of intratumoral (or intracavitary) brain delivery of IL13 dTc in a human application, potentially arming the dTc with a suicide gene (37) to eliminate persisting dTc if leaking out of the tumor site to cause systemic or CNS toxicity. In this regard, the lack of toxicity in the rats from the IL13 dTc injection is mildly reassuring for a local delivery, in as much as human IL13 and IL13-based dTc will react with the rodent IL13Rα1 ortholog. Alternatively, still-more-selective mutations or antibodies could be developed for a safe human clinical application; ideally, one would have a recognition domain in the CAR that is absolute for the α2 receptor with no α1 reactivity whatsoever.
ACKNOWLEDGMENTS

We thank Dr Raj Puri and Dr Waldemar Debinski for expert discussions. This work was supported by the Roger Williams Hospital Brain Tumor Fund and an award from the Rhode Island Brain and Spine Tumor Foundation.
REFERENCES


27


<table>
<thead>
<tr>
<th>Group</th>
<th>Median survival days (Range)</th>
<th>Long Term Survivors (%) (&gt;120d)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor, no treatment (n=4)</td>
<td>35 (35-38)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Tumor + UnTd T cells (n=10)</td>
<td>40 (29-53)</td>
<td>0</td>
<td>&lt;0.03 vs no treatment</td>
</tr>
<tr>
<td>Tumor + IL13 dTc (n=11)</td>
<td>88 (47-120+)</td>
<td>28</td>
<td>&lt;0.0001 vs no treatment;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001 vs UnTd T cells</td>
</tr>
</tbody>
</table>
FIGURE LEGENDS

Figure 1. Construction of IL13 CAR.  
A. Plasmid map of IL13-CAR.pMFG.  
The IL13.CD28.ζ CAR expression cassette was constructed and cloned into BamHI and NotI sites of the MFG retroviral expression vector plasmid.  
B. CARs with different signal sequences (IL13, immunoglobulin heavy chain), with and without CD8a hinge, were constructed.  
Efficacy of CAR expression on the transduced T cells was tested by flow cytometry, with % positive listed in each panel.

Figure 2. Expression of CAR on transduced T cells.  
A. Graphic representation of the IL13-CAR showing monomeric and dimeric forms.  
B. Western blot of CAR expression on membranes of transduced T cells, confirming monomer and dimer size bands versus control UnTd T cells.  
C. Flow cytometric profiles of IL13-CAR expression on transduced T cells, with % positive listed.  
MFI of positive fractions was similarly high among all constructs (>10,000).

Figure 3. T cell signaling via different CAR formats assessed by IL2 production by transduced T cells.  
A. Flow cytometric profile of IL13Rα1 and IL13Rα2 expression on U251 glioma cells and Thp-1 cells.  
B. Bar graph representing specific IL2 secretion by IL13-CAR transduced T cells upon co-culturing with either IL13R (a1+a2-) Thp-1 cells (white bars) or IL13R (a1-a2+) U251 glioma cells (black bars) after background subtractions (Methods).  
IL2 levels are normalized to the % modified cells (range 20%-24%) and expressed in pg/10^6 modified T cells/24 hr.  
Error bars represent standard deviation from the mean of triplicate results.

Figure 4. Functional characterization of IL13-CAR T cells.  
A. Cytotoxic effects of IL13-CAR transduced versus Untransduced T cells on U251 glioma cells (Blue bars) or control HUVEC cells (Red bars).  
Left panel shows cytotoxicity after 5h of coculture with an E:T ratio of 5:1.  
Right panel shows cytotoxicity after 22h of coculture with E:T ratio of 0.5:1.  
Error bars
represent standard deviation from the mean of triplicate results. B. Cytokine secretion by
IL13-CAR transduced or Untransduced T cells upon co-culture with U251 glioma cells (Blue
bars) or control HUVEC cells (Red bars). *Left panel* IL2; *Right panel* interferon-gamma (IFNγ).
Cytokine levels expressed as pg/10⁶ total T cells/24 hr, uncorrected for modified fraction (30%).
Error bars represent standard deviation from the mean of triplicate results. C. dTc cell
proliferation upon co-culturing 1:1 with control Daudi cells (*Left panel*) and U251 glioma cells
(*Right panel*) on days 0, 3, 9 and 14 and cell counts assayed (♀: UnTd T cells; ♂, IL13-CAR T
cells). D. Enrichment of IL13-CAR T cells upon co-culture with stimulators. T cell expansions in
C. with either U251 glioma cells or control Daudi cells were assayed by flow on day 0 and day
14. *Top:* Untransduced (UnTd) T cells *Bottom:* IL13 CAR transduced T cells. X-axis represents
IL13 CAR expression, while Y-axis represents cell count in the histogram plots.

**Figure 5. Successful suppression of human glioma xenografts by IL13-CAR+ T cells.**
Rats with 6-day established U251 glioblastoma tumors were randomized into 3 groups for
treatment on day 0: (a) CAR + T cells, (b) UnTd T cells, and (c) no treatment. A. Representative
brain histology. At day 7 post T cell injection, progressing and regressing tumors were
assessed by H&E (a, b) and anti-CD3 mAb staining (c, d, e). H&E (a) UnTd: A 4 mm tumor is
shown. (b) dTc: An indistinct band of tumor with a 5 mm zone of associated inflammation.
Immunostaining: Anti-CD3 immunostaining showed increased T cells in the dTc treated tumors
(d, e) versus tumors treated with UnTd T cells (c). B. T2-weighted MR images of tumor-
bearing animals at indicated times following treatment. For each rat, three acquired slices are
displayed at each time point to span the tumor zone. No visual tumor (open arrow) was
observed in animals treated with CAR+ T cells. In contrast, large tumors (solid arrow) were
observed in control groups animals that grew progressively. C. Kaplan-Meier progression-free
survival.
Appendix

DERIVATIONS:

I. We model growth of a mixed culture of CAR+ and CAR- cells as the sum of the independent growths of the two cell types, adjusted by the starting proportion of each cell type:

\[ y_3 = (1-f_1)y_1 + f_1y_2 \]  

(1)

In this, \( y_1 \) = fold-expansion of CAR negative cells (the growth rate of the unstimulated culture), \( y_2 \) = fold-expansion of CAR+ cells upon stimulation, \( y_3 \) = fold-expansion of the mixed culture, \( f_1 \) = starting fraction of dTc in mixed culture.

On rearrangement to solve for \( y_2 \), eq. (1) yields:

\[ y_2 = \frac{1}{f_1} (y_3 - (1-f_1)y_1) \]  

(2)

The fold-change in growth for the dTc on antigen stimulation is given as:

\[ n = \frac{y_2}{y_1} \]  

(3)

II. The ratio of growth rate constants is derived as follows. The relative growth of the two cell fractions is given by \( y_1 = e^{k_1t} \) and \( y_2 = e^{k_2t} \). The log of both sides yields \( \log y_1 = k_1t \) and \( \log y_2 = k_2t \). Dividing the second equation by the first yields the ratio of rate constants:

\[ \frac{k_2}{k_1} = \frac{\log y_2}{\log y_1} \]  

(4)

III. The change in proliferation rate for dTc upon stimulation [eq. (3)] can also be inferred from the fractions of dTc in the culture at the start (\( f_1 \), as above) and at the end (\( f_2 \)) of the experiment. \( f_1y_2 \) is the expansion of dTc in the mix in eq. (1), in which \( y_3 \) is the total expansion of all cells. Therefore, the new fraction is given by:

\[ f_2 = \frac{f_1y_2}{y_3} = \frac{f_1y_2}{(1-f_1)y_1 + f_1y_2} \]  

(5)

Rearrangement of equation (5) yields the ratio of dTc to control expansions, analogous to eq. (3):

\[ n = \frac{y_2}{y_1} = \frac{1-f_1}{f_1} \cdot \frac{f_2}{1-f_2} \]  

(6)
Figure 1

A

![Diagram of a circular molecular structure with labels such as pUC origin, 5' LTR, PsI, AmpR, 3' LTR, CAR, and restriction enzyme sites like BamHI, Avr II, Mfe I, Hpa I, Not I, Mlu I, and Hinc II. The structure contains a label indicating IL13-pMFG 7346 bp.]

B

Untransduced controls

<table>
<thead>
<tr>
<th>hIL3 signal</th>
<th>IL13</th>
<th>CD8H</th>
<th>CD3 TM</th>
<th>CD28</th>
<th>CD3ζ</th>
</tr>
</thead>
<tbody>
<tr>
<td>VHCAMP signal</td>
<td>IL13</td>
<td>CD8H</td>
<td>CD3 TM</td>
<td>CD28</td>
<td>CD3ζ</td>
</tr>
<tr>
<td>hIL3 signal</td>
<td>IL13</td>
<td>CD3 TM</td>
<td>CD28</td>
<td>CD3ζ</td>
<td></td>
</tr>
<tr>
<td>VHCAMP signal</td>
<td>IL13</td>
<td>CD3 TM</td>
<td>CD28</td>
<td>CD3ζ</td>
<td></td>
</tr>
</tbody>
</table>

Graph showing percentage distributions for different conditions.
Figure 3

A

B

IL2 (pg/10^6 cells/24h)

IL13 WT

IL13 mutant

THP-1  U251

monomer  dimer

monomer  dimer
**Figure 4**

A

5h (E:T = 5:1)

- U251 IL13R (α1±α2+)
- HUVEC IL13R (α1±α2-)

22 h (E:T = 0.5:1)

- U251 IL13R (α1±α2+)
- HUVEC IL13R (α1±α2-)

B

- IL2 (ng/ml/2x10^6 T cells)
- INF-γ (ng/ml/2x10^6 T cells)

C

DAUDI IL13R (α1^+α2^-)

- T cell number (10^6)

U251 IL13R (α1^-α2^+)

- T cell number (10^6)

D

- UnTd
- IL13 CAR transduced

DAUDI

<table>
<thead>
<tr>
<th>IL13R (α1^-α2^-)</th>
<th>IL13R (α1^-α2^+)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.0%</td>
<td>3.3%</td>
</tr>
</tbody>
</table>

U251

<table>
<thead>
<tr>
<th>IL13R (α1^-α2^-)</th>
<th>IL13R (α1^-α2^+)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1%</td>
<td>41.0%</td>
</tr>
</tbody>
</table>

Day 0

Day 14
Figure 5

A

H & E

anti-CD3

UnTd  IL13 CAR

a  b

c  d  e

B

Tumor only  UnTd  IL13 CAR

week 1

week 2

week 3

C

Percent Survival

Time (days)

100
80
60
40
20
0

Tumor only (n=4)

Tumor + IL13CART cells (n=11)

Tumor + untransduced T cells (n=10)
Clinical Cancer Research

Suppression of Human Glioma Xenografts with 2nd Generation IL13R-Specific Chimeric Antigen receptor-Modified T Cells

Seogkyoung Kong, Sadhak Sengupta, Betty M. Tyler, et al.

Clin Cancer Res Published OnlineFirst September 10, 2012.

Updated version
Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-12-0319

Supplementary Material
Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2012/09/10/1078-0432.CCR-12-0319.DC1
http://clincancerres.aacrjournals.org/content/suppl/2012/10/31/1078-0432.CCR-12-0319.DC2

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.